Table 2 Comprehensive assessment of the NP_004439.2:p.Y772_A775dup variant across clinical interpretation knowledgebases
From: A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer
Resource | ERBB2 variant name | Evidence | Document ID | Interpretation |
|---|---|---|---|---|
CIViC | M774INSAYVM | Level B, 2-star | Does not support sensitivity/response to dacomitinib in NSCLC | |
M774INSAYVM | Level C, 4-star | Supports sensitivity/response to afatinib in lung adenocarcinoma | ||
M774INSAYVM | Level C, 3-star | Supports sensitivity/response to afatinib in lung adenocarcinoma | ||
M774INSAYVM | Level C, 3-star | Supports sensitivity/response to trastuzumab emtansine in lung adenocarcinoma | ||
M774INSAYVM | Level D, 3-star | Supports sensitivity/response to afatinib and rapamycin (combination) in NSCLC | ||
Kinase domain mutation | Level C, 4-star | Supports sensitivity/response to trastuzumab in lung adenocarcinoma | ||
Kinase domain mutation | Level C, 3-star | Supports sensitivity/response to afatinib in lung adenocarcinoma | ||
OncoKB | Exon 20 insertions | Level 4 | Supports response to AP32788 in NSCLC | |
Oncogenic mutations | Level 3A | PMID: 23220880 | Supports response to neratinib in breast cancer and NSCLC | |
CGI | inframe insertion A775YVMA | Early trials | Responsive to ado-trastuzumab emtansine in lung cancer | |
inframe insertion A775YVMA | Early trials | Responsive to neratinib in cancer | ||
proximal exon 20 | Early trials | PMID: 26598547 | Responsive to afatinib, neratinib, lapatinib or trastuzumab in lung adenocarcinoma | |
PMKB | exon(s) 20 insertion | Tier 2 | PMID: 22761469 | Associated with sensitivity to some ERBB2 inhibitors in lung adenocarcinoma |
PMID: 16818618 | ||||
PMID: 25152623 | ||||
JAX-CKB | Y772_A775dup | Clinical study | PMID: 26964772 | Conflicting response to afatinib in lung adenocarcinoma |
Y772_A775dup | Phase II | PMID: 29420467 | Predicted sensitive to neratinib in Her2-receptor-negative breast cancer | |
Y772_A775dup | Phase II | PMID: 29420467 | Predicted resistant to neratinib in urinary bladder cancer and NSCLC | |
Y772_A775dup | Preclinical | PMID: 26545934 | Sensitive to afatinib in lung cancer | |
Y772_A775dup | Preclinical | PMID: 26545934 | No benefit to gefitinib in lung cancer | |
Y772_A775dup | Preclinical | PMID: 28363995 | Sensitive to neratinib in advanced solid tumor | |
exon 20 insertion | Clinical study | PMID: 28167203 | Predicted sensitive to afatinib or trastuzumab in NSCLC | |
exon 20 insertion | Clinical study | PMID: 26964772 | Predicted sensitive to afatinib in lung adenocarcinoma | |
exon 20 insertion | Phase II | PMID: 29420467 | Predicted sensitive to neratinib in Her2-receptor-negative breast cancer | |
exon 20 insertion | Phase II | PMID: 29420467 | No benefit to neratinib in NSCLC | |
exon 20 insertion | Preclinical | Sensitive to AP32788 in advanced solid tumor | ||
MolecularMatch | Y772_A775dup | Level 1B | Confers sensitivity to afatinib in patients with neoplasm of lung | |
Y772_A775dup | Level 2C | PMID: 26598547 | Confers sensitivity to trastuzumab in patients with neoplasm of lung | |
Y772_A775dup | Level 2D | PMID: 22325357 | Confers sensitivity to afatinib in patients with neoplasm of breast | |
A775_G776insYVMA | Level 1A | Confers sensitivity to afatinib in patients with neoplasm of lung | ||
A775_G776insYVMA | Level 2C | Confers sensitivity to afatinib in patients with neoplasm of breast | ||
A775_G776insYVMA | Level 2D | Confers sensitivity to neratinib in patients with neoplasm of breast |
